Vaxcyte, Inc.
PCVX
$31.16
-$0.29-0.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | 75.00M | 75.00M | 75.00M |
| Gross Profit | -- | -- | -75.00M | -75.00M | -75.00M |
| SG&A Expenses | 105.68M | 92.90M | 81.87M | 74.49M | 67.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 635.87M | 569.55M | 604.05M | 577.16M | 511.32M |
| Operating Income | -635.87M | -569.55M | -604.05M | -577.16M | -511.32M |
| Income Before Tax | -509.63M | -463.93M | -507.65M | -497.19M | -436.82M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -509.63 | -463.93 | -507.65 | -497.19 | -436.82 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -509.63M | -463.93M | -507.65M | -497.19M | -436.82M |
| EBIT | -635.87M | -569.55M | -604.05M | -577.16M | -511.32M |
| EBITDA | -626.91M | -562.54M | -599.03M | -573.11M | -507.88M |
| EPS Basic | -3.98 | -3.80 | -4.55 | -4.62 | -4.22 |
| Normalized Basic EPS | -2.49 | -2.37 | -2.84 | -2.89 | -2.64 |
| EPS Diluted | -3.98 | -3.80 | -4.55 | -4.62 | -4.22 |
| Normalized Diluted EPS | -2.49 | -2.37 | -2.84 | -2.89 | -2.64 |
| Average Basic Shares Outstanding | 511.84M | 487.84M | 455.17M | 433.14M | 413.95M |
| Average Diluted Shares Outstanding | 511.84M | 487.84M | 455.17M | 433.14M | 413.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |